Coherus Oncology, Inc. Income Statement
CHRS|6 years of annual SEC 10-K data (FY2014-FY2019)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Revenue has declined at a 6.4% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|
| Revenue | - | $0 | $1.6M | $31.1M | $2.8M | $1.9M |
| Cost of Revenue | $17.1M | - | - | - | - | - |
| SG&A Expense | $137.0M | $94.2M | $71.3M | $17.6M | $7.5M | $5.5M |
| R&D Expense | $94.2M | $110.2M | $162.4M | $78.2M | $31.3M | $34.9M |
| Operating Income | $107.8M | -$204.4M | -$232.1M | -$64.7M | -$36.0M | -$38.5M |
| Interest Expense | $17.6M | $9.7M | $9.6M | $3.9M | $5.3M | $1.5M |
| Income Tax | $2.9M | $0 | $0 | $0 | - | - |
| Net Income | $89.8M | -$209.3M | -$238.2M | -$87.1M | -$53.6M | -$33.0M |
| EPS (Basic) | -$4.48 | - | - | -$1.67 | - | - |
| EPS (Diluted) | -$4.48 | -$3.04 | -$6.01 | -$1.67 | -$16.10 | -$15.85 |
| Shares Outstanding | 68.3M | 59.8M | 45.8M | 39.0M | 33.3M | 4.8M |
| Operating Margin | - | - | -14918.8% | -207.9% | -1308.4% | -2028.3% |
| Profit Margin | - | - | -15306.6% | -280.1% | -1949.7% | -1738.7% |